Recursion Pharmaceuticals, Inc.

RXRX

N/A

NASDAQBiotechnology🇺🇸North America800 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jul 15, 2026

29w

Drug Pipeline

Drug Name	Phase	Indication	Designations
GTAEXS617	Phase 2	Advanced Solid Tumor	-
Placebo	Phase 2	Familial Adenomatous Polyposis	-
REC-4881	Phase 2	AXIN1 Gene Mutation	-
REC-994	Phase 2	Cerebral Cavernous Malformation	-
REC-1245	Phase 2	Unresectable	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

Placebo Phase 2 Results Expected

July 2026~Placebo

Primary completion for Placebo trial (NCT05552755) in Familial Adenomatous Polyposis

Source

Phase 2

REC-4881 Phase 2 Results Expected

July 2026~REC-4881

Primary completion for REC-4881 trial (NCT05552755) in Familial Adenomatous Polyposis

Source

Regulatory Approvals

RXRX News

Recursion Pharmaceuticals, Inc.

RXRX

N/A

NASDAQBiotechnology🇺🇸North America800 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jul 15, 2026

29w

Drug Pipeline

Drug Name	Phase	Indication	Designations
GTAEXS617	Phase 2	Advanced Solid Tumor	-
Placebo	Phase 2	Familial Adenomatous Polyposis	-
REC-4881	Phase 2	AXIN1 Gene Mutation	-
REC-994	Phase 2	Cerebral Cavernous Malformation	-
REC-1245	Phase 2	Unresectable	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

Placebo Phase 2 Results Expected

July 2026~Placebo

Primary completion for Placebo trial (NCT05552755) in Familial Adenomatous Polyposis

Source

Phase 2

REC-4881 Phase 2 Results Expected

July 2026~REC-4881

Primary completion for REC-4881 trial (NCT05552755) in Familial Adenomatous Polyposis

Source

Regulatory Approvals

RXRX News